AKUMS existing six state-of-the-art manufacturing facilities have huge per day capacity to produce formulations in practically all dosage forms, i.e. Tablets, Capsules, Soft gels, Dry Syrups, Liquid Orals, Powder in Sachet, Dry & Liquid Injections, Pre-filled Syringes, Large Volume Parenterals (up to 100 ml), Lyophilized Injections and Eye / Ear / Nasal Drops in FORM FILL & SEAL and THREE PIECE Packs.
AKUMS first Plant, commissioned in the year 2004 is the State-of-the-Art manufacturing facility producing tablets, capsules, soft - Gelatin capsules & Dry Syrups with huge PER DAY manufacturing capacity in all sections and has separate blocks for Beta Lactums, Non-Beta Lactums, Cephalosporin & Penicillin preparations.
AKUMS first Plant, commissioned in the year 2004 is the State-of-the-Art manufacturing facility producing tablets, capsules, soft - Gelatin capsules & Dry Syrups with huge PER DAY manufacturing capacity in all sections and has separate blocks for Beta Lactums, Non-Beta Lactums, Cephalosporin & Penicillin preparations.
Location: India, Delhi
Employees: 10001+
Phone: 011 4751 1000
Founded date: 2004
Investors 1
| Date | Name | Website |
| - | Quadria Ca... | quadriacap... |
Mentions in press and media 13
| Date | Title | Description |
| 14.02.2026 | Akums Delivers Strong Q3 FY26 Performance with 14.8% Revenue Growth and 21% Adj EBITDA Growth | New Delhi, Delhi, India Akums Drugs & Pharmaceuticals Ltd., India’s Largest Contract Development and Manufacturing Organizations (CDMO), announced its financial results for the third quarter of FY26. Q3 FY 26 saw strong performance acro... |
| 13.02.2026 | Q3 Results Today Highlights: NBCC (India), IPCA Lab, NLC Industries Q3 profit up, Alkem Lab shares slump, Rategain & Blue Jet profit fall | Data Analysis. Pen with business report on financial advisor desk. Concept of business planning , accounting, business analysis,financial planning services. istock photo for BL | Photo Credit: utah778 Q3 Results Today, 13th Feb 2026 Highlig... |
| 28.12.2025 | ‘Resigning due to Delhi pollution’: Akums Finance head steps down as AQI crosses 400-mark | - |
| 13.11.2025 | Akums Reports Q2 FY26 Results; Strengthens International Presence | New Delhi, Delhi, India Akums Drugs & Pharmaceuticals Ltd., India’s Largest Contract Development and Manufacturing Organizations (CDMO), announced its financial results for the second quarter of FY26. The CDMO segment remained the key c... |
| 23.08.2025 | Akums and The Govt of The Republic of Zambia Announce Joint Venture to Establish Pharmaceutical Manufacturing Facility in Zambia | Lusaka, Zambia | Delhi, India Akums, a leading player in pharmaceutical manufacturing, and The Government of The Republic of Zambia (GRZ), have announced a partnership to set up a manufacturing facility in Zambia to provide high quality and... |
| 08.08.2025 | Akums Reports Q1 FY26 with 19% YoY Adj EBITDA Growth; Achieves 1,000 DCGI Approvals | New Delhi, Delhi, India Akums Drugs and Pharmaceuticals Ltd., India’s largest contract development and manufacturing organization (CDMO), has announced its consolidated financial results for the quarter ended June 30, 2025. This quarter con... |
| 01.07.2025 | Sun Pharma, Mankind, Cipla Lead Recruitments at SGT University's Mega Job Fest: PharmaPICK 2.0 | Gurugram, Haryana, India SGT University, Gurugram, a NAAC A+ accredited institution renowned for its industry-aligned academics and placement-focused initiatives, successfully hosted PharmaPICK 2.0, A Mega Job Fest 2025, at its vibrant camp... |
| 27.05.2025 | Akums Reports Q4 FY25 with 12.4% Revenue Growth, FY25 Adj. EBITDA Remained Strong at 12.3% | New Delhi, Delhi, India Akums Drugs and Pharmaceuticals Ltd., India’s largest contract development and manufacturing organization (CDMO), has announced its consolidated financial results for the quarter and fiscal year ending March 31, 2025... |
| 14.01.2025 | Quadria Capital's $100 Million Bet on Aragen: A Strategic Move in Pharma Outsourcing | In the ever-evolving landscape of pharmaceuticals, the recent $100 million investment by Quadria Capital in Aragen Life Sciences marks a significant milestone. This deal, announced on January 13, 2025, positions Aragen as a key player in th... |
| 13.01.2025 | Quadria Capital invests $100 million in Aragen to boost pharma outsourcing services | Contract research, development and manufacturing organisation Aragen has secured a $100 million investment from Quadria Capital, an Asia healthcare-focused private equity fund. This gives Quadria a minority stake in Aragen, at a valuation o... |
Show more